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Abstract 
Whilst there remains limited intervention to address the damage to the developing 
brain, current multidisciplinary management of cerebral palsy (CP) needs to minimise the 
impact of secondary musculoskeletal complications. A focus on comorbidities, to maximize 
function for activity and participation by supporting the child and family in their environment 
is required. Comprehensive clinical guidance was published by NICE earlier this year. This 
article aims to provide a practical clinical approach to the child and family, based on: 
1) Art: Empathy, listening and weighing up the clinical picture of the 
child and family in context; diagnosis, the need for support and space, and care co-
ordination at the right time. 
2) Science: the current science in CP care is rapidly expanding in terms 
of plasticity, pathophysiology, functional assessments, and treatments. 
 
  
Introduction 
Definition and epidemiology  
“Cerebral palsy (CP) describes a group of permanent disorders of movement and 
posture, causing activity limitation that are attributed to non-progressive disturbances that 
occurred in the developing foetal or infant brain. The motor disorders of CP are often 
accompanied by disturbances of sensation, perception, cognition, communication and 
behaviour; by epilepsy and by secondary musculoskeletal problems.”  
 
This current definition of CP 1 recognizes the importance of the International 
Classification of Functioning Disability and Health: Children and Youth Version (ICF-CY2); 
to facilitate our understanding of the impact of CP on the child and family, encapsulating 
functional problems. (Figure 1) 
The overall prevalence of CP in developed countries is 2–3 per 1000 live births, 
though in susceptible premature infants (<28 weeks gestation) it rises to 100 per 10003.  
Pathophysiology 
 Rapid central nervous system growth occurs in-utero, until 5 months postnatally. At 
this time the brain is susceptible to malformation, infection, damage and disruption of its 
emerging blood supply. The “watershed areas” are most susceptible to damage: in the pre-natal 
brain the ‘periventricular zone’ of the motor cortex, at term the subcortical white matter. At 
term hypoxic damage also occurs in the cells with the highest metabolic need: the basal 
ganglia, the ‘locomotor driving system’ of our motor control, where reflex patterns of 
movement are unconsciously coordinated. 4  
Fluid motor patterns initiated by desire and anticipation of function, are modified by 
inputs such as peripheral sensory interaction, vision and balance (equilibrium and adaptive 
systems). Intracerebral reflex loops organise the descending upper motor control of the 
peripheral lower motor neurons via, among others, the corticospinal tracts. When this 
complex motor system is impaired, the fluidity of control breaks down, leading to the ‘non-
progressive movement disorder’4.  
There is a caveat to the “non-progressive” definition. Following insult there is 
significant potential for cortico-spinal tract re-organisation:  ‘neuroplasticity’.  This may be 
beneficial, or may cause further impairment5.  
 
Classification of CP  
Motor pattern and distribution                                                              
The distribution and motor pattern observed are associated with the site of the 
underlying primary pathophysiology, (Table 1)  
The Surveillance of Cerebral Palsy in Europe (SCPE) classification uses the terms 
‘unilateral’ or ‘bilateral’ and focuses on the type of motor disorder seen 6. The 
limitation of this classification is early delineation between spasticity and dystonia. 
 Cortico-spinal tract damage results in the “upper motor neurone syndrome”. This 
includes disinhibition of the spinal reflex arc and muscle over activation: 
spasticity -velocity dependent hypertonia4. 
 Damage to the basal ganglia leads to patterns of sustained muscle contraction of 
usually antagonistic muscle pairs causing abnormal postures or joint position: 
dystonia and involuntary movements which include chorea and athetosis: 
dyskinesia4. 
Many children with CP have a mixed pattern of spasticity and dystonia7, with other 
features of the upper motor neurone syndrome: weakness, poor selective motor control, 
sensory inattention, difficulties with motor planning, and non-neurological tissue changes.  
Severity 
The gross motor functional classification system (GMFCS8) (Figure 2) is a reliable 
prognostic indicator of motor function. Other developmental functional classification systems 
have also been developed. (Figure 1)  
 
Clinical care  
The clinician needs a clear understanding of the underlying aetiology and 
pathophysiology. Further, they need be able to communicate this effectively to the family and 
other professionals working with the child, understand the child and family in context: how 
the diagnosis has affected them, and how management of the condition will impact on them 
throughout the life course. 
Identification, diagnosis and information sharing 
Parents report dissatisfaction with the disclosure of a CP diagnosis. Many children 
referred to tertiary clinics have been labelled with cerebral palsy, but the family may have not 
fully understood this description. They often have questions regarding motor function (will 
their child walk?), communication potential, educational provision, medical interventions, 
participation, and family life 9.  
Review of the potential causation helps the clinician to answer the many questions, 
and also support the family emotionally, assessing understanding of information previously 
shared 10.  
Although cranial imaging is often performed in the neonatal period, repeat imaging at 
2 years is more reliable due to myelination and grey matter maturation. If there is diagnostic 
uncertainty (i.e. mismatch of history and clinical presentation, signs of neurological 
regression) MRI, alongside metabolic and genetic investigations should be pursued. 
Otherwise, MRI alone is unlikely to change CP management 11. 
Clinical examination should focus on motor function, distribution and nature of motor 
signs; but must also include assessment of other development, including functional 
assessments. Cognition, language (receptive and expressive; speech or alternative 
communication), and associated sensory impairments may have more influence on 
participation in community, school, and family activities than motor function4,11.  
Never underestimate parent understanding, they are the expert on their child 9. 
Explain how the child’s current clinical signs match the background history. Show scans and 
explain how the pattern of cerebral insult directly relates to their child’s presentation, and 
how this may help to predict prognosis 12. 
Management of motor impairments 
The mainstay of multi-disciplinary management of CP is therapy, equipment and 
support. The goals of therapies (including physiotherapy, occupational therapy, and speech 
therapy) are:  
 Promoting development according to potential. 
 Providing equipment or support to facilitate participation in home and school. 
 Detection and prevention of secondary complications. 
There are a vast array of therapy interventions, orthoses and equipment that may be 
used, with a wide variation in evidence base. Therapists rely on parent and other carer 
delivered interventions, so support must be given to training them 13. 
Medical interventions 
The choice of medication is considered according to the predominant motor pattern. 
These include systemic oral medications or focal treatment with botulinum toxin 14. 
Principles of treatment are: start low, escalate slowly, assess response, and withdraw if 
evidence of adverse effects or no benefit 4,11. (Table 2) 
Treatment with botulinum toxin should be carefully considered, with clinical 
assessment by a multi-disciplinary team with expertise 14. Goals must be identified and post 
treatment re-assessment is essential. Communication with local teams should ensure 
adjunctive therapy intervention or orthoses are well co-ordinated.  
Surgical Interventions 
Orthopaedic 
Referral pathways between community and tertiary multi-disciplinary teams and 
surgeons with expertise in CP should be clear. Proposed UK-wide implementation of the 
Cerebral Palsy Integrated Pathways Scotland (CPIPS)15 hip surveillance programme aims to 
facilitate this. Monitoring of motor progress, growth and physical parameters is key. The 
focus is on surveillance: preventative surgical intervention for hip subluxation and early 
identification of neuromuscular scoliosis. Guided growth for knee flexion contractures, 
epiphysiodesis for limb length discrepancy and muscle lengthening remain common 
procedures.  
Neurosurgical approaches 
 Intrathecal baclofen pump insertion (ITB)16, Selective Dorsal Rhizotomy (SDR)17 and 
deep brain stimulation (DBS)18 are all available at highly specialist centres in the UK. 
Detailed assessment and patient selection is essential, and there needs to be clear 
communication between the specialist centre and all other multi-disciplinary teams involved 
with the child and family, to ensure close monitoring and follow up is maintained. 
Other treatments: keeping up with knowledge 
As no “cure” is available multiple other treatments are considered. Complimentary 
therapies, off label medications, and stem cell therapies are often discussed by families 
guided by information on the internet. 
Understandably, parents are likely to want to try anything that may improve their 
child’s quality of life. This leaves them vulnerable to interventions that may be costly, not 
improve their child’s functioning, and/or cause harm. It is important that clinicians show 
respect for the parents’ knowledge and research, but feel confident to guide them towards 
accurate and honest information regarding realistic expectations 9.  
Medical management of general health and other co-morbidities 
Co-morbidities are significant drivers of poor tone and motor control.  Sleep 
deprivation, distress due to pain or feeding difficulties are often the most disruptive factors 
for children and families. Empathy and management of these, alongside treatment of the 
other frequent co-morbidities e.g., epilepsy, GI dysmotility (gastro-oesophageal reflux, 
delayed gastric emptying, constipation) recurrent respiratory infection, sialorrhoea and 
orthopaedic complications is paramount. Often if these are appropriately managed, further 
medications or management of tone may not be required.4,11 
Educational support 
Accurate and timely identification of the child’s full developmental profile is essential 
to support appropriate educational provision. Implementation of the Education, Health and 
Care Plan (EHCP) facilitates mandated annual reviews and ensures the child and family 
views are heard. Practical considerations include cognitive, communication and sensory 
issues, and how the child’s needs may be met in the context of motor impairment. Therapy 
programmes are important, but delivery of these should be balanced with educational 
priorities.  
Social and leisure support  
The most important thing for a child is to participate in and to enjoy activities. “Put 
the fun into function!” Helping participation by signposting to appropriate, activities, 
organisations, social care, charities and support is a significant role of the clinician, and is 
highly valued by families.  
Life course approach  
Management of cerebral palsy goes beyond childhood. That is, supporting children 
and their families throughout adolescence, and into becoming a participating adult, whatever 
their motor function and other developmental or health needs. Recently published NICE CP11 
guidance and EHCP19 planning is now extended to age 25 years. There is current paediatric 
input into the development of adult CP guidance. There needs to be development of adult 
physicians with CP expertise in order to have appropriate services to “transition” to. 
Conclusion 
The modern day CP clinician should be a grounded general paediatrician who 
considers the child in the context of their family and environment, and supports them to 
become a participating adult. There is little complicated with respect to CP management, 
rather a range of general paediatric presentations in the context of a distraction of an 
underlying neurodevelopmental diagnosis. 
 
  
 References 
 
1 Rosenbaum P, Paneth N, Leviton A, Goldstein M, Bax M, Damiano D, Dan B, Jacobsson B. A 
report: the definition and classification of cerebral palsy April 2006. Dev. Med. Child Neurol. Suppl. 
2007; 109: 8-14. 
2 World Health Organization. International Classification of Functioning, Disability, and Health: 
Children & Youth Version: ICF-CY. Geneva, Switzerland: World Health Organization; 2007. 
3 Johnson A. Prevalence and characteristics of children with cerebral palsy in Europe. Dev. 
Med. Child Neurol. 2002; 44: 633-40. 
4 Fairhurst C. Cerebral palsy: the whys and hows. Arch. Dis. Child. Educ. Pract. Ed. 2012; 97: 
122-31. 
5 Eyre JA. Corticospinal tract development and its plasticity after perinatal injury. Neurosci. 
Biobehav. Rev. 2007; 31: 1136-49. 
6 Cans C. Surveillance of cerebral palsy in Europe: a collaboration of cerebral palsy surveys and 
registers. Surveillance of Cerebral Palsy in Europe (SCPE). Dev. Med. Child Neurol. 2000; 42: 816-24. 
7 Rice J, Skuza P, Baker F, Russo R, Fehlings D. Identification and measurement of dystonia in 
cerebral palsy. Dev. Med. Child Neurol. 2017; 59: 1249-55. 
8 Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Gross motor function 
classification system (GMFCS). Dev. Med. Child Neurol. 1997; 39: 214-23. 
9 Kisler J. Parental reaction to disability. Paediatrics and Child Health 2014; 24: 331-6. 
10 Shevell AH, Shevell M. Doing the "talk": disclosure of a diagnosis of cerebral palsy. J. Child 
Neurol. 2013; 28: 230-5. 
11 National Institute for Health and Care Excellence. Cerebral palsy in under 25s: assessment 
and management. NICE guideline 2017; NG62. 
12 Redshaw ME, Harvey ME. Explanations and information-giving: clinician strategies used in 
talking to parents of preterm infants. BMC Pediatr. 2016; 16: 25. 
13 Novak I, McIntyre S, Morgan C, Campbell L, Dark L, Morton N, Stumbles E, Wilson S-A, 
Goldsmith S. A systematic review of interventions for children with cerebral palsy: state of the 
evidence. Dev. Med. Child Neurol. 2013; 55: 885-910. 
14 Heinen F, Desloovere K, Schroeder AS, Berweck S, Borggraefe I, van Campenhout A, 
Andersen GL, Aydin R, Becher JG, Bernert G, Caballero IM, Carr L, Valayer EC, Desiato MT, Fairhurst 
C, Filipetti P, Hassink R-I, Hustedt U, Jozwiak M, Kocer SI, Kolanowski E, Krägeloh-Mann I, Şehim K, 
Mäenpää H, Mall V, McArthur P, Morel E, Papavassiliou A, Pascual-Pascual I, Pedersen SA, 
Plasschaert FS, Irene van der P, Remy-Neris O, Renders A, Di Rosa G, Steinlin M, Tedroff K, Valls JV, 
Viehweger E, Molenaers G. The updated European Consensus 2009 on the use of botulinum toxin for 
children with cerebral palsy. Eur. J. Paediatr. Neurol. 2010; 14: 45-66. 
15 The Association of Paediatric Chartered Physiotherapists. Cerebral Palsy Integrated Pathway 
- Developing a UK-wide programme. http://apcp.csp.org.uk/cerebral-palsy-integrated-pathway-
developing-uk-wide-programme2018) 
16 Dan B, Motta F, Vles JSH, Vloeberghs M, Becher JG, Eunson P, Gautheron V, Lütjen S, Mall V, 
Pascual-Pascual SI, Pauwels P, Røste GK. Consensus on the appropriate use of intrathecal baclofen 
(ITB) therapy in paediatric spasticity. Eur. J. Paediatr. Neurol. 14: 19-28. 
17 Grunt S, Becher JG, Vermeulen RJ. Long-term outcome and adverse effects of selective 
dorsal rhizotomy in children with cerebral palsy: a systematic review. Dev. Med. Child Neurol. 2011; 
53: 490-8. 
18 Vidailhet M, Yelnik J, Lagrange C, Fraix V, Grabli D, Thobois S, Burbaud P, Welter M-L, Xie-
Brustolin J, Braga M-CC, Ardouin C, Czernecki V, Klinger H, Chabardes S, Seigneuret E, Mertens P, 
Cuny E, Navarro S, Cornu P, Benabid A-L, LeBas J-F, Dormont D, Hermier M, Dujardin K, Blond S, 
Krystkowiak P, Destée A, Bardinet E, Agid Y, Krack P, Broussolle E, Pollak P. Bilateral pallidal deep 
brain stimulation for the treatment of patients with dystonia-choreoathetosis cerebral palsy: a 
prospective pilot study. The Lancet Neurology 2009; 8: 709-17. 
19 Department for Education & Department of Health. Special educational needs and disability 
code of practice: 0 to 25 years. 2015. 
Tables and Figures 
 
Table 1: Clinical presentations of cerebral palsies according to cerebral insult 
Clinical motor 
presentation 
Aetiology Timing Pathophysiology Clinical Features 
Hemiplegia 
Spasticity 
Dystonia or mixed. 
Vascular insult 
(most frequently) 
Pre-natal 
Perinatal 
Postnatal 
Grey or white matter in 
arterial territory 
Dependent on site and extent 
of vascular lesion: variable  
Epilepsy, learning, sensory 
impairment  
Bilateral – 
predominantly 
lower limb 
spasticity 
Prematurity Pre-natal (3rd 
trimester) IVH 
Periventricular white 
matter 
Cognition may be  well 
preserved, epilepsy unlikely 
Bilateral -
predominantly 
spasticity 
Congenital infection Pre-natal Grey and white matter Cognitive impairment, 
epilepsy +/- other sensory 
impairments 
Bilateral – 
predominantly 
dystonia and 
dyskinesia 
Mild-moderate 
hypoxic ischaemic 
encephalopathy 
Perinatal 
Postnatal 
Basal ganglia 
(deep grey matter) 
Cognition often well 
preserved, epilepsy unlikely 
Bilateral – mixed 
spasticity, dystonia 
and other 
associated sensory  
Profound hypoxic 
ischemic 
encephalopathy 
 
Peri or postnatal 
infection  
Perinatal  
Postnatal 
Grey and white matter Severe motor impairment 
Bulbar dysfunction 
Sensory abnormalities 
Cognitive impairment and 
epilepsy 
 
 
 
  
Table 2: Summary of muscle relaxants and antidystonic medicines:  
Green = Frequently used as First Line; Amber = Used as second line; recommend specialist input; Red = Caution to 
use or rarely used in children 
 Background and effect Side effect Dose 
Muscle relaxant 
Baclofen 
 
The commonest drug for adult and 
childhood hypertonia, used since the 
1970s 
 
It works on the pre and postsynaptic 
GABAB receptors of the spine to 
reduce excitation of the spinal reflex 
arc 
It has difficulty crossing the 
blood–brain barrier and therefore 
high-peripheral doses of oral 
medicine are necessary for effect 
As such, it has a narrow 
therapeutic window before 
significant side effects of truncal 
hypotonia, sedation and increased 
seizure propensity are seen 
Start 
5 mg, three times a day, halved in very small children 
 
Max 
2-3 mg/kg/day. Increased slowly to effect or side effect  
Occasional escalation higher with specialist 
supervision. 
 
Tizanidine Used increasingly frequently in the 
adult population 
 
This central α2-noradrenergic agonist 
is generally better tolerated than 
baclofen in adults 
There is limited experience of its 
use in children 
 
Sedation, hypotension, agitation, 
depression and gastrointestinal 
problems are the main side effects 
 
Uncertain start 
1mg twice daily <10 years 
2mg od >10 years 
Max 
0.05 mg/kg/day 
2mg three times a day >12 years 
 
Diazepam Other benzodiazepines work at the 
spinal GABA level by increasing 
presynaptic inhibition. They are 
extremely effective, especially in 
short-term use if emergency muscle 
relaxation is needed or sleep disturbed 
Highly sedating and tolerance is 
easily developed 
Benzodiazepine withdrawal 
syndrome is a significant concern 
with long-term use, especially in 
the very young 
Start 
0.25 mg/kg twice daily 
Max 
Infant 2.5 mg twice daily Child 5 mg twice daily 
>12 years 10 mg twice daily 
 
Dantrolene Works at the muscle level by 
inhibiting calcium release from the 
sarcoplasmic reticulum 
It causes global weakness and 
rarely, though catastrophically, 
liver failure in around 1% of 
patients 
 
Start 
0.5 mg/kg twice daily for 4 days, increase to three times 
a day then four times a day 
Max 
2mg/kg four times a day or 100 mg four times a day 
Antidystonic  medicine 
Trihexyphenidyl Probably the antidystonic medicine 
with the greatest therapeutic benefit 
 
 
This anticholinergic agent works at 
the level of the basal ganglia 
Side effects come from its mode 
of action and include 
disorientation, gastrointestinal 
disturbances (especially 
constipation), urinary retention 
and xerostomia (excessively dry 
mouth) 
Start 
0.5, 1 or 2 mg twice daily, increase weekly to twice 
daily, then three times a day, then 0.5 mg – 2 mg/week 
Max 
1 mg/kg/day Exceptionally high doses are often 
necessary, up to 
1.6 mg/kg/day 
LevoDopa plus 
Cocareldopa 
 
If there is any possible doubt about 
diagnosis from history and/or 
neuroimaging, then a trial of 
LevoDopa should be given. Rarely a 
DOPA responsive dystonia can mimic 
CP with extraordinary benefits for the 
individual if treated early 
It is given with a peripheral 
inhibitor – Co Careldopa 
(Sinemet, Madopar) to minimise 
side effects of nausea, insomnia 
and increased chorea 
Laevo:Cocarel – 4:1 ration at low 
dose, 10:1 ratio at high dose 
Check liver function 6 monthly 
Start 
1–2 mg/kg/day LDopa in —four 
– six doses 
 
Max 
Increase every 2–3 days to max 10 mg/kg/day 
 
Clonidine  α2 adrenergic agonist 
 
Increasingly used for dystonia, 
especially where there is distress/ 
agitation. Highly useful in peri-
operative management. Can be used 
as “rescue” or regular in acute or 
community 
Hypotension, sedation, dry mouth 
 
Tolerance and escalation of doses 
often required 
Test dose (3microgram/kg) if commencing for acute 
symptoms advised on ward ( BP monitoring) 
 
Can gradually escalate lower dose in community.  
Start 
1microgram/kg nocte  
 
Max 
Can be used up to 4 hourly if required 3microgram/kg. 
Occasional escalation higher with specialist 
supervision. 
Gabapentin GABA- analogue, modulates GABA 
biosythesis. but activity also through 
voltage gated Ca2+ channels 
 
Increasing evidence of benefit in 
dystonia especially if associated with 
choreoathetosis 
Sedation, fatigue, dizziness, 
occasional irritability. 
Start 
5mg/kg/day (3 divided doses) 
 
Max  
Licensed – 50mg/kg/day (6-12yrs) 
BNF -70mg/kg/day 
Tetrabenazine Rarely used in paediatric practice. 
 
Dopamine depletors, prevent 
neurotransmitter degradation 
Akathesia, depression and other 
mood disorders, agitation 
 
Start 
12.5 mg increase slowly to max 
Max 
100 mg/day 
Note. CP = cerebral palsy, DOPA = dihydroxyphenylalanine, GABA = γ-amino butyric acid. 
Figure 1: International Classification of Functioning Disability and Health: Children and Youth 
Version (ICF-CY) – related to CP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note. Disability is not solely a medical impairment; it is also a social construct. Therefore, context is an 
important influence. The ICF-CY offers a holistic conceptual framework and common terminology for 
recording problems involving functions and structures of the body, activity limitations and participation 
restrictions, and environmental factors important for children and youth.  
 
GMFCS = Gross Motor Funcional Classification System 
MACS = Manual Ability Classification System 
EDACS = Eating and Drinking Functional Classification System 
CFCS = Communication Functional Classification System 
VFCS = Visual Functional Classification System  
Health Condition 
Cerebral Palsy 
Body Structure and Function 
Motor pattern and distribution 
Gross motor skills: GMFCS 
Upper limb function: MACS 
Feeding skills: EDACS 
Communication skills: CFCS 
Vision: VFCS 
Pain 
 
Activity 
Play  
Learning 
Peer interaction 
Participation 
Peer interaction 
Communication 
Vision 
Environmental factors 
Physical space 
Where they live? 
Home  
School 
Access to suitable activities 
Personal factors 
Child’s choice 
Parent/carer choice 
Age of child 
Figure 2: Gross Motor Functional Classification System (GMFCS) 
 
 
Table 3: Summary of Neurosurgical Interventions for CP 
 
Neurosurgical 
intervention 
Appropriate Patient Selection (evidence) Complications and limitations 
Motor severity Type of Movement 
Disorder 
Spasticity Dystonia 
Dyskinesia 
Intrathecal 
Baclofen Pump 
(ITB) 
GMFCS IV-V YES YES Frequent refills required 
Weakness 
Sudden withdrawal – status dystonicus 
 Catheter breakage 
 Pump failure 
Infection 
Skin breakdown 
Selective Dorsal 
Rhizotomy 
(SDR) 
GMFCS II-III YES NO Weakness  
Poor selective motor control 
Sensory disturbance 
Long-term functional mobility may not be improved 
Irreversible 
Deep Brain 
Stimulation 
(DBS) 
GMFCS IV-V NO YES Infection 
Evidence base limited in secondary dystonia (CP) 
Irreversible ( although may be switched off) 
 
  
Table 4: Current Challenges for CP care- and how we may overcome them. 
Challenges Opportunities Top tips 
 
Diagnosis 
Parents still report 
anxiety and 
dissatisfaction with the 
diagnostic journey 
 
 
 
 
 
 
Transitional care and 
care of adults  with 
cerebral palsy  
NICE CP Guidance 
 
Recommendations for 
follow up of “high risk 
infants”  
 
NICE CP Quality 
Standards 
 
 
NICE CP Guidance for 
adults has paediatric 
representation on the 
guidelines committee. 
 
 
NICE CP guidelines now 
for 0-25 years. 
 
Power of open discussion with families: honest 
sharing of basic pathology and science, highlighting 
what we do and do not know.  
 
Human kindness and empathy is essential. 
 
Paucity of clinical evidence 
Limited evidence base 
for almost all 
interventions 
(therapeutic, medical and 
surgical) for children 
with CP. 
 
Generation of evidence 
challenging in 
heterogenous population, 
with multiple 
confounders, limited 
outcome measures, and 
need for large scale 
longitudinal data for 
traditional body structure 
outcomes. 
 
Multiple interventions: 
old: “inherited practice” 
and an exponential 
number of new 
approaches.  
Real drive in literature – 
and by professionals and 
families to search and 
generate good quality 
evidence. 
 
 
Honest and open 
discussion regarding 
what we do and don’t 
know. Novak article in 
2013 (although 
limitations) gave 
comprehensive review of 
evidence state. 
 
 
 
Recognition and priority 
setting for research in 
paediatric neurodisabilty 
are focussing on 
outcomes meaning to 
children and families.  
(BACD- SRG*  
James Lind Alliance) 
Don’t miss what is already known: it takes 15-20 
years from lab to clinical intervention: now is time to 
move research and change attitudes: 
 Research needs to shift to ICY-CY(2001) 
rather than focusing on body structure. It is 
important to fund research into meaningful 
outcomes for young people (e.g., activity 
and participation). 
 CST reorganisation and pathophysiology 
research shows exciting avenues for early 
intervention. 
 
Engaging young people with CP and their parents in 
research is essential to develop meaningful outcomes 
for families.  
 Benefit of qualitative or mixed methods 
research should be acknowledged. 
 
The internet and access to information 
Parents may be 
susceptible to 
overestimating the value 
of low quality 
information and advice, 
leaving them vulnerable 
to interventions that may 
be costly, not improve 
The internet can be 
empowering and 
beneficial for accessing 
support. 
 
 
Show respect for the parents’ knowledge and 
research but feel confident to guide them towards 
accurate and honest information regarding realistic 
expectations, and towards critical review of the 
available evidence. 
 
Parents and clinicians can refer to the Peninsula 
Cerebra Research Unit (PENCRU) evidence 
their child’s functioning, 
and/or cause harm. 
NICE CP Quality 
Standards 
Recommendations 
 
 
summaries, available on their website 
(http://www.pencru.org/). 
 
Other helpful websites to signpost include: 
Hemihelp: www.hemihelp.org.uk 
Contact a Family: www.contact.org.uk 
Whizz Kids: www.whizz-kidz.org.uk 
CP Sport: www.cpsport.org 
SCOPE: www.scope.org.uk 
British Paralympics Association 
www.parasport.org.uk 
English Federation of Disability Sport 
www.efds.co.uk 
 
  
 Self-Assessment Questions: 
1) A five year old boy with bilateral CP GMFCS III is referred for tone management.  He 
was born at 27 weeks gestation and his MRI shows peri-ventricular leukomalacia. 
Which of the following interventions may be considered? 
a. A therapy programme to include strengthening 
b. Baclofen medication 
c. Targeted botulinum toxin injections 
d. Deep brain stimulation 
e. Selective dorsal rhizotomy 
2) A three year old girl is referred for assessment and tone management. She was born 
at term by emergency lower segment caesarian section due to poor CTG, and 
developed perinatal hypoxic ischaemic encephalopathy requiring cooling. She 
presents with a pattern of bilateral cerebral palsy, GMFCS IV with mixed spasticity 
and dystonia. Which of the following statements are true? 
a. Hip surveillance x-ray is required if not previously done. 
b. Detailed visual assessment is recommended 
c. MRI scan is mandatory 
d. The clinician should reassure the family that she will be able to walk 
independently in future 
e. Medication such as trihexyphenidyl may be beneficial 
3) A teenager (age 17) who has CP: GMFCS V is referred with ongoing painful dystonia. 
He has had previous bilateral hip surgery. Please indicate which interventions should 
be considered: 
a. Treatment for constipation 
b. Targeted Botulinum toxin injections 
c. Re-referral to orthopaedics 
d. Selective dorsal rhizotomy 
e. Adding dantrolene to his medications 
4) A three year old boy with CP: GMFCS V, mixed spasticity and dystonia, is referred for 
recurrent chest infections. Which of the following statements are true? 
a. Speech and language therapy assessment of feeding is recommended. 
b. A normal videofluoroscopy eliminates the possibility of recurrent aspiration. 
c. Secretion management may improve if trihexyphenidyl is used as an anti-
dystonic medication. 
d. Neuromuscular scoliosis may be causing a pattern of restrictive reduced 
pulmonary function. 
e. Parents should be advised that he should not be enrolled into nursery as he 
may catch more infections. 
5) An eleven year old girl with CP: GMFCS III, predominant lower limb spasticity, has 
just started mainstream secondary school. Which of the following statements are 
appropriate for her education, health and care plan. 
a. She should have access to both her k-walker and a wheelchair at school 
b. She should not participate in PE with her peers 
c. Additional time may be required in moving between lessons 
d. She will require input from physiotherapy and occupational therapy 
throughout her secondary school years. 
e. She may require additional time to complete exams. 
Answers: 
1) A,B,C, E 
2) A,B, E 
3) A,B,C 
4) A,C,D 
5) A,C,D,E 
 
 
 
 
